AXIM® Biotechnologies Nutraceutical Division Announces Cannabinoid-Based Wellness Gum Product Line at Benzinga Cannabis Capital Conference
NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech,” “AXIM” or “the Company”) (OTCQB: AXIM), a world leader in cannabinoid research and development, announced today that its nutraceutical division, AXIM® Wellness, has launched its flagship nutraceutical product line, AXIM® Wellness Gum (“Wellness Gum”), at the Benzinga Cannabis Capital Conference in Chicago, IL. AXIM has also begun accepting consumer and wholesale orders on its new Wellness Gum website.
This new patented product line, which offers consumers with the best absorption, best bioavailability and the best way to consume cannabinoids, features:
- Wellness Gum formulated with 5 mg of cannabidiol (CBD) and 25 mg of full-spectrum hemp oil.
- Wellness Gum PM formulated with 5 mg of CBD, 25 mg of full-spectrum hemp oil, melatonin, L-Tryptophan and vitamin B3.
- Wellness Gum Extra Strength formulated with 10 mg of CBD and 50 mg of full-spectrum hemp oil.
In the coming months, the Wellness Gum product line will expand to offer additional cannabinoid-based products formulated with targeted ingredients such as caffeine, green tea, and ginseng.
AXIM’s new Wellness Gum website offers a streamlined and easy-to-navigate design that allows visitors to learn about Wellness Gum products, the science behind AXIM’s proprietary chewing gum delivery mechanism, and order products through its online store.
“We are excited for the launch of the Wellness Gum product line during the Benzinga Cannabis Capital Conference and look forward to discussing our new cannabinoid-based nutraceutical gum line with the cannabis community,” said John W. Huemoeller II, Chief Executive Officer of AXIM® Biotech. “AXIM is also proud to offer retailer and practitioner wholesale programs that give business owners the opportunity to earn additional revenue while offering their customers the benefits of our full-spectrum CBD gum such as the highest bioavailability and absorbency on the market.”
Through the site, retailers and practitioners will have access to bulk ordering and wholesale pricing for customers and patients. The programs also offer participants the opportunity to earn commission on sales made online or in stores.
AXIM also intends to continue expanding the reach of its Wellness Gum line across the nation through individual sales representatives.
To schedule a meeting with AXIM during the Benzinga Cannabis Capital Conference, please email firstname.lastname@example.org.
To visit the Wellness Gum website, please visit wellnessgum.com.
For more information about the retailer wholesale program, please visit wellnessgum.com/retail.
For more information about the practitioner wholesale program, please visit wellnessgum.com/practitioners.
About AXIM® Biotechnologies
AXIM® Biotechnologies, Inc. (AXIM) is a world leader in the research and development of cannabinoid-based pharmaceutical and nutraceutical products. Along with building a robust intellectual property portfolio, AXIM is focused on clinical development programs that bring more efficacy and/or lower side effects than existing alternatives and require small to medium budgets and timelines to bring to market which presents a high added-value to the pharmaceutical field.
AXIM's flagship product, MedChew® with dronabinol, is planned to undergo a bioequivalence study in the near future to fast track through FDA as an alternative delivery mechanism. For more information, please visit www.AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of AXIM Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
Corporate Contact Info:
North American Address:
45 Rockefeller Plaza, 20th Fl.
New York, NY 10111, USA
P. 844 294 6246
Industrieweg 40, Unit B4
3401 MA IJsselstein
Investor Relations Contact:
Released October 22, 2019